Substance / Medication

Ergocalciferol

Overview

Active Ingredient
ergocalciferol
RxNorm CUI
4018

Indications

Ergocalciferol Capsules, USP are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin D resistant rickets, and familial hypophosphatemia.

Labeler: REMEDYREPACK INC.Updated: 2026-01-28T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Ergocalciferol Capsules, USP are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin D, and hypervitaminosis D.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

7 trials linked to this intervention

7
Total Trials
2
Recruiting
3
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Effect of Ergocalciferol on β-Cell Function in New-Onset Type 1 Diabetes: A Secondary Analysis of a Randomized Clinical Trial.
Nwosu Benjamin Udoka, Parajuli Sadichchha, Sharma Rohit B et al. · JAMA Netw Open · 2024
PMID: 38441899RCTFull text (PMC)
Improving vitamin D status in bariatric surgery subjects with monthly high-dose ergocalciferol.
Galyean Shannon, Syn David, Subih Hadil S et al. · Int J Vitam Nutr Res · 2022
PMID: 34521264RCT
Standard and high dose ergocalciferol regimens for treatment of hypovitaminosis D in epileptic children and adolescents.
Vichutavate Suchavadee, Suwanpakdee Piradee, Likasitthananon Napakjira et al. · J Pediatr Endocrinol Metab · 2022
PMID: 36190481RCT
High-dose versus low-dose ergocalciferol for correcting hypovitaminosis D after fragility hip fracture: a randomized controlled trial.
Jarusriwanna Atthakorn, Phusunti Suchat, Chotiyarnwong Pojchong et al. · BMC Geriatr · 2021
PMID: 33478397RCTFull text (PMC)
Treatment Effect of Ergocalciferol on Bone Metabolism Indexes and Parathyroid Hormone in Hemodialysis Patients.
Bashardoust Bahman, Zakeri Anahita, Fouladi Nasrin et al. · Iran J Kidney Dis · 2018
PMID: 30595565RCT
Plasma transport of ergocalciferol and cholecalciferol and their 25-hydroxylated metabolites in dairy cows.
Hymøller L, Jensen S K · Domest Anim Endocrinol · 2017
PMID: 27940098RCT
Ergocalciferol Supplementation in Hemodialysis Patients With Vitamin D Deficiency: A Randomized Clinical Trial.
Miskulin Dana C, Majchrzak Karen, Tighiouart Hocine et al. · J Am Soc Nephrol · 2016
PMID: 26677862RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Ergocalciferol (substance)
SNOMED CT
23433006
UMLS CUI
C0014695
RxNorm CUI
4018
Labeler
REMEDYREPACK INC.

Clinical Data

This intervention maps to 3 entities in the Healos knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
7
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.